Segment & Geographic Data Quant-Grade Normalized (live API) API & CSV Delivery

Crescent Biopharma Inc's Business Segments

Crescent Biopharma Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.

Segment Data As of Q1 FY2026

Reportable Segments

Per the company's own filing, this quarter

Largest Segment

Reportable

100% of revenue

Total Revenue

$ 1

Consolidated, this quarter

Regions Reported

Geographic regions, this quarter

API endpoints for this dataset

                        https://api.csimarket.com/api/v1/companies/CBIO/segments                    

                        https://api.csimarket.com/api/v1/companies/CBIO/geographic                    

                        https://api.csimarket.com/api/v1/companies/CBIO/exposure                    

Programmatic access for models, analytics, and integration workflows.

Pull these exact ratios programmatically

Get an API key License this feed for redistribution / AI →

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Revenue Share by Reportable Segment - Q1 FY2026

Reportable100%

Revenue by Reportable Segment - Q1 FY2026

Segment	Period	Revenue (Millions)	% of Total	Operating Income
Reportable	Q1 FY2026	$ 1	100%	-

Description of Crescent Biopharma Inc

Catalyst Biosciences Inc. is a clinical-stage biopharmaceutical company specializing in the development of novel therapies for hematology and rare diseases. The company utilizes a proprietary protease engineering platform to develop highly specific and potent proteases. Its lead product candidate, Marzeptacog alfa (activated) (MarzAA), is an engineered coagulation factor VIIa designed for the treatment of hemophilia A or B with inhibitors and Factor VII deficiency. MarzAA aims to provide enhanced efficacy and a prolonged half-life compared to existing treatments. Catalyst Biosciences' pipeline also includes CB 2679d/ISU304, a subcutaneously administered Factor IX variant for severe hemophilia B, and CB 2782, a protease therapy targeting systemic complement-mediated diseases. The company maintains a strong research and development focus, supported by collaborations with academic institutions and biotechnology companies. Its protease engineering platform underpins its drug development efforts and is protected by a portfolio of patents covering related technologies and product candidates.